Delayed Neurotoxicity With CAR-T Therapy in Myeloma: What Clinicians Need To Know

In this episode of ASTCT Talks, Dr. Rahul Banerjee sits down with Dr. Kenneth Lim and Dr. Yi Lin of Mayo Clinic to discuss a critical and emerging topic in CAR T-cell therapy: delayed neurotoxicities following cilta-cel treatment in multiple myeloma. They break down the clinical features of nerve palsies and Parkinsonism-like symptoms, share diagnostic and treatment strategies and explore emerging predictive markers like absolute lymphocyte count. Given that cilta-cel is increasingly being used in second-line myeloma treatment and is even being studied in first-line treatment to replace stem cell transplantation, this conversation is a timely and insightful look at improving patient outcomes in CAR T-cell therapy.